Market Access News | pharmaphorum

News

Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.

News

Vertex gets FDA approval for its non-opioid pain drug suzetrigine, the first new class of pain medicine in the US in more than 20 years.

News

President Trump will continue Medicare drug pricing negotiation but intends to look for improvements to the scheme according to CMS.

News

ALK-Abello's Acarizax for dust mite allergy should soon be available through the NHS in England, Wales and Northern Ireland, but not in Scotland.

News

Robert F Kennedy Jr's first confirmation hearing was a fractious affair, marked by tough questions about his prior anti-vaccine stance.

News

Novo Nordisk's Ozempic has become the first drug in the GLP-1 class to be cleared to prevent worsening kidney disease in type 2 diabetics.